Cargando…

Genetic alternations and immune characteristics in patients with small cell lung cancer

Detalles Bibliográficos
Autores principales:	Zhang, Chenyue, Zhao, Chenglong, Wang, Haiyong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504138/ https://www.ncbi.nlm.nih.gov/pubmed/34427988 http://dx.doi.org/10.1002/cac2.12208

Ejemplares similares

Neoadjuvant chemotherapy remodels the tumor immune microenvironment by increasing activated and cytotoxic T cell, decreasing B cells and macrophages in small cell lung cancer
por: Shang, Xiaoling, et al.
Publicado: (2023)

Intratumor heterogeneity is associated with less CD8(+) T cell infiltration and worse survival in patients with small cell lung cancer
por: Zhang, Chenyue, et al.
Publicado: (2022)

CD44, a marker of cancer stem cells, is positively correlated with PD-L1 expression and immune cells infiltration in lung adenocarcinoma
por: Zhang, Chenyue, et al.
Publicado: (2020)

Loss of heterozygosity related to TMB and TNB may predict PFS for patients with SCLC received the first line setting
por: Zhang, Chenyue, et al.
Publicado: (2021)

Construction of immune-related and prognostic lncRNA clusters and identification of their immune and genomic alterations characteristics in lung adenocarcinoma samples
por: Li, Jia, et al.
Publicado: (2020)

Molecular subtyping of small‐cell lung cancer based on mutational signatures with different genomic features and therapeutic strategies
por: Wang, Haiyong, et al.
Publicado: (2022)

The negative relationship between patients with NSCLC harbored STK11/KEAP1 copy number variation and immune microenvironment infiltration
por: Zhang, Chenyue
Publicado: (2021)

Orchestrating smart therapeutics to achieve optimal treatment in small cell lung cancer: recent progress and future directions
por: Zhang, Chenyue, et al.
Publicado: (2023)

Better cancer specific survival in young small cell lung cancer patients especially with AJCC stage III
por: Wang, Haiyong, et al.
Publicado: (2017)

Clinical characteristics and outcomes of Chinese patients with KRAS‐mutant non‐small cell lung cancer after chemotherapy
por: Zheng, Yawen, et al.
Publicado: (2021)

A 5-Gene Signature Is Closely Related to Tumor Immune Microenvironment and Predicts the Prognosis of Patients with Non-Small Cell Lung Cancer
por: Li, Jia, et al.
Publicado: (2020)

Surgery as a Potential Treatment Option for Patients With Stage III Small-Cell Lung Cancer: A Propensity Score Matching Analysis
por: Zhang, Chenyue, et al.
Publicado: (2019)

Immune checkpoint inhibitors combined with tyrosine kinase inhibitors is the treatment option of previously treated advanced non-small cell lung cancer harboring EGFR or ALK genetic aberration
por: Yang, Xiaobo, et al.
Publicado: (2022)

Whole-Exome Sequencing Uncovers Specific Genetic Variation Difference Based on Different Modes of Drug Resistance in Small Cell Lung Cancer
por: Tang, Ning, et al.
Publicado: (2022)

The landscape of m(6)A regulators in small cell lung cancer: molecular characteristics, immuno-oncology features, and clinical relevance
por: Zhang, Chaoqi, et al.
Publicado: (2021)

No benefit of chemotherapy in Osimertinib-treated postoperative non-small cell lung cancer patients
por: Li, Feng, et al.
Publicado: (2021)

Construction of an integrated prognostic classifier model for predicting the efficacy of immune checkpoint inhibitor therapy in non‐small cell lung cancer
por: Lin, Zhihuan, et al.
Publicado: (2020)

Profiling of DNA damage and repair pathways in small cell lung cancer reveals a suppressive role in the immune landscape
por: Jin, Renjing, et al.
Publicado: (2021)

Effective treatment of MET-amplified non-small cell lung cancer patients with crizotinib: a case description
por: Tang, Mingyue, et al.
Publicado: (2023)

Integrative analysis of multi‐omics data reveals the heterogeneity and signatures of immune therapy for small cell lung cancer
por: Chen, Yabin, et al.
Publicado: (2021)

The predictive value of tumor mutation burden for immune checkpoint inhibitors therapy in non-small cell lung cancer is affected by patients’ age
por: Wu, Yongfeng, et al.
Publicado: (2020)

Dual immune checkpoint blockade for non-small cell lung cancer patients with PD-L1 high expression: calling an end?
por: Peng, Ling, et al.
Publicado: (2021)

Identification of a circulating immunological signature predictive of response to immune checkpoint inhibitors in patients with advanced non‐small cell lung cancer
por: Khatir, Wassila, et al.
Publicado: (2022)

A 5-Genomic Mutation Signature Can Predict the Survival for Patients With NSCLC Receiving Atezolizumab
por: Lin, Jiamao, et al.
Publicado: (2021)

Merkel cell polyomavirus and non-small cell lung cancer
por: Shuda, M, et al.
Publicado: (2013)

Addition of metformin to non‐small‐cell lung cancer patients with or without diabetes
por: Chen, Hua‐Fen, et al.
Publicado: (2022)

Relationship between obstructive lung disease and non-small cell lung cancer
por: Akamine, Takaki, et al.
Publicado: (2020)

Genomic Variations and Immune-Related Features of TMB, PD-L1 Expression and CD8(+) T Cell Infiltration in Chinese Pulmonary Sarcomatoid Carcinoma
por: Zhang, Chenyue, et al.
Publicado: (2022)

Therapeutic utility of Lung-MAP: ushering into an era of genomic and biomarker-driven clinical trials
por: Zhang, Chenyue, et al.
Publicado: (2021)

Epiphora following chemotherapy with pemetrexed in patients with advanced non-small cell lung cancer
por: Jung, Yun Duk, et al.
Publicado: (2017)

Implementation of patient reported outcomes in definitive chemoradiation for non-small cell lung cancer
por: Vogel, Jennifer, et al.
Publicado: (2020)

Prognostic factors for recurrence in patients with surgically resected non-small cell lung cancer
por: Satoh, Hiroaki, et al.
Publicado: (2022)

Whole exome sequencing in Chinese mucinous pulmonary adenocarcinoma uncovers specific genetic variations different from lung adenocarcinoma
por: Zhang, Chenyue, et al.
Publicado: (2022)

Immunomodulatory effects of chemotherapy on blood lymphocytes and survival of patients with advanced non-small cell lung cancer
por: Aldarouish, Mohanad, et al.
Publicado: (2019)

Clinicopathological Difference and Survival Impact of Patients with c-SCLC and SCLC
por: Zhang, Chenyue, et al.
Publicado: (2021)

Epigenetic modifications of the immune-checkpoint genes CTLA4 and PDCD1 in non-small cell lung cancer results in increased expression
por: Marwitz, Sebastian, et al.
Publicado: (2017)

Advanced non-small cell lung cancer associated with hemophagocytic syndrome in a cachectic patient
por: Asai, Nobuhiro, et al.
Publicado: (2012)

Involved-field radiotherapy in limited-stage small-cell lung cancer
por: Chien, C-R, et al.
Publicado: (2007)

Neoadjuvant therapy for locally advanced non-small cell lung cancer: TKIs or immunotherapy?
por: Zhang, Zhenyang, et al.
Publicado: (2020)

Molecular analysis of cell-free DNA identifies distinct molecular features in patients with chemosensitive and chemorefractory small cell lung cancer
por: Zhang, Jie, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_qbairg2h729phblg3hqeec6qj1